FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid Leukaemia By Ogkologos - November 26, 2024 543 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ASC4FIRST study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR How Your Primary Care Provider Can Help You Throughout Your Cancer... March 5, 2021 Isolated Hepatic Perfusion with Melphalan Improves Response Rate and PFS in... April 5, 2023 FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC February 5, 2021 What to Know About Returning to Work After Cancer Treatment: An... February 15, 2024 Load more HOT NEWS Percentage of Cancer Patients Who Are Eligible for and Respond to... A Combination of Durvalumab-Tremelimumab with mFOLFOX6 Is Tolerable with Promising Activity... A Better Biomarker for Cancer Immunotherapy? First-Line Pembrolizumab Continues to Show Durable Clinical Benefit After 5 Years...
